Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Multiple Myeloma 188Lymphoma, Mantle-Cell 34Neoplasms, Plasma Cell 32Lymphoma 32Recurrence 26Lymphoma, Follicular 20Waldenstrom Macroglobulinemia 18Lymphoma, Non-Hodgkin 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Lymphoma, Large B-Cell, Diffuse 13Lymphoma, B-Cell, Marginal Zone 13Carcinoma, Non-Small-Cell Lung 13Immunoglobulin Light-chain Amyloidosis 10Neoplasms 9Leukemia, Myeloid, Acute 9Lymphoma, B-Cell 8Renal Insufficiency 7Leukemia, Lymphocytic, Chronic, B-Cell 7Leukemia 7Hodgkin Disease 6Lymphoma, T-Cell, Peripheral 5Lymphoma, T-Cell 5Prostatic Neoplasms 4Myelodysplastic Syndromes 4Kidney Neoplasms 4Carcinoma, Renal Cell 4Breast Neoplasms 4Brain Neoplasms 4Amyloidosis 4Stomach Neoplasms 3

Interventions

Paclitaxel 2Injections 2toripalimab 1tislelizumab 1surufatinib 1sotorasib 1osimertinib 1netrin-1 inhibitor NP137 1lazertinib 1fluzoparib 1camrelizumab 1Panitumumab 1PM 01183 1Nivolumab 1Ipilimumab 1HMPL-013 1Erlotinib Hydrochloride 1Dexamethasone 1Calcium Dobesilate 1Bortezomib 1Bevacizumab 13-(8-amino-1-(2-phenylquinolin-7-yl)imidazo(1,5-a)pyrazin-3-yl)-1-methylcyclobutanol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Advanced Solid Tumors × Bortezomib × Clear all
NCT02057380 2024-11-20

A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial

Astellas Pharma Inc

Phase 2 Completed
13 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡